JUN 15, 2016 08:00 AM PDT
Novel PET radiochemistries: Improving understanding and detection of disease
SPONSORED BY: PerkinElmer, Inc.
8 35 4547

  • Professor of Radiology, Mayo Clinic
      Timothy R. DeGrado, PhD is a Professor of Radiology at the Mayo Clinic (Rochester, MN) and directs a molecular imaging laboratory. Dr. DeGrado has 30+ years' experience in radiochemistry, radioisotope production, radiopharmacology, PET imaging, and radiopharmaceutical development. He has focused his career on developing metabolic PET radiopharmaceuticals, and has brought several agents through preclinical, animal, and clinical translation, including 18F-fluorocholine, which is now used routinely in many countries for imaging of prostate cancer.
    • Associate Professor, ETH Zurich
        Roger Schibli, PhD is an Associate Professor in the Department of Chemistry and Applied Biosciences (ETH Zurich), and Head of the Center for Radiopharmaceutical Science (CRS), a joint endeavor between the ETH Zurich, the Paul Scherrer Institute and the University Hospital Zurich. Professor Schibli studied Chemistry at the University of Basel, Switzerland and performed his doctoral thesis under the supervision of Professor Thomas Kaden. After his graduation, he spent two years at the University of Missouri (Columbia, MO) as a post-doctoral fellow. He was appointed Assistant Professor (tenure track) for Therapeutics Technologies at the Institute of Pharmaceutical Sciences (ETH Zurich) in 2004 and was tenured in 2009.

        Professor Schibli's research interests cover targeted tumor diagnosis and therapy using radiolabeled compounds. Apart from the chemical modification and radioactive labeling of molecules, his group places emphasis on the biological and pharmacological characterization and optimization of the radioactive compounds including non-invasive PET and SPECT imaging. New, medically relevant radionuclides for his preclinical and clinical studies are produced at the cyclotron and neutron facilities of the ETH and the Paul Scherrer Institute.

      DATE: June 15, 2016
      TIME:  08:00AM PDT, 11:00AM EDT, 3:00PM GMT

      Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical translation from mouse models to man. PET is often the favored imaging modality of choice due to its high sensitivity and resolution. Today, PET is seeing a rapid growth in the number of new imaging agents under development, and an increased utilization of PET imaging to interrogate disease progression in small animal preclinical models. Once considered a specialized imaging modality, PET is transitioning to the mainstream of the preclinical molecular imaging field and PerkinElmer’s G-Platform is breaking down some of the barriers to PET adoption. PET is now positioned to be the molecular imaging modality of choice for a variety of emerging applications in drug discovery and basic science research.

      In this webinar Drs. Timothy DeGrado from the Mayo Clinic and Roger Schibli from ETH Zurich will discuss novel radiochemistry approaches their groups are employing to gain further understanding of disease development and progression. Dr. DeGrado’s publication in EJNMMI Research in 2015 highlighted a new cell labeling technique that allows longitudinal imaging of cell trafficking over the course of weeks in a quantitative, non-invasive manner. Dr. Schibli’s radiochemistry efforts have led to the development of several new radioisotopes for in vivo imaging applications and therapeutic intervention. Imaging data acquired on the PerkinElmer’s G4 PET/X-ray and G8 PET/CT systems is enabling the development of these novel PET imaging agents with potential clinical applications. Join us for our thought provoking discussion of the current and future states of preclinical PET imaging. Drs. DeGrado and Schibli will also answer your questions at the conclusion of the webinar.


      Show Resources
      Loading Comments...